Mimrylo™
rusfertide for injection

Specialty Network Fact Sheet

INDICATION

MIMRYLO is indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV).

ORDERING AND DISTRIBUTION

MIMRYLO™ (rusfertide) is available through both specialty pharmacies and practices that dispense.

Ordering through specialty distributors (Qualified entities* only)

MIMRYLO may be purchased through the following distribution partners and dispensed through accounts that have a medically integrated pharmacy:

Cardinal Health Monday–Friday: 7:00 am - 6:00 pm CT 1-855-855-0708 1-866-677-4844 (on call/after hours) Website: https://vantus.cardinalhealth.com/home	**McKesson Plasma and Biologics** Phone: 1-877-625-2566 Fax: 1-888-752-7626 Email: mpborders@mckesson.com Online ordering portal: connect.mckesson.com
Oncology Supply Phone: 1-800-633-7555 Fax: 1-800-248-8205 Email: service@oncologysupply.com	**McKesson Specialty Health** Phone: 1-800-482-6700 Fax number: 1-855-824-9489 Email: oncologycustomersupport@mckesson.com Online Ordering Portal: mscs.mckesson.com
ASD Healthcare Monday–Thursday: 7:00 am - 6:30 pm CT Friday: 7:00 am - 6:00 pm CT Phone: 1-800-746-6273 Fax: 1-800-547-9413 Email: service@asdhealthcare.com	*Qualified entities for direct purchase include hospitals, physician practices, and institutions that have been licensed by a state agency to dispense pharmaceutical products to appropriate patients. Direct purchase is not available to specialty pharmacy providers or retail pharmacies who are not themselves part of a qualified entity. Eligible government entities include the Department of Defense (DoD), Department of Veterans Affairs, and 340B-covered entities.

Ordering through specialty pharmacies

Choose one of the following specialty pharmacies in the MIMRYLO network:

Biologics Phone: 1-800-850-4306 Fax: 1-800-823-4506 E-prescription (if applicable): NPI 1487640314; NCPDP 3430369 Website: biologics.mckesson.com	**In-Office Dispensing** To arrange in-office dispensing, please contact your specialty distributor or Takeda Oncology Here2Assist® Monday–Friday: 8:00 am - 8:00 pm ET Phone: 1-844-817-6468, Option 5
Onco360 Phone: 1-877-662-6633 Fax: 1-877-662-6355 E-prescription (if applicable): NPI 1679618151 Website: www.onco360.com	If your institution does not have medically integrated dispensing capabilities or chooses not to fill a MIMRYLO prescription through your medically integrated pharmacy, MIMRYLO may be ordered and filled through one of these in-network specialty pharmacies. Sending a MIMRYLO prescription to a pharmacy that is either not your institution's medically integrated pharmacy or outside of the limited distribution network may result in delay or nonfulfillment of the prescription.

Please see Important Safety Information on page 3 and accompanying full Prescribing Information.

How MIMRYLO is supplied

- MIMRYLO for injection is supplied in a carton for each individual dosage strength comprising a single-dose vial containing a sterile, preservative-free, white to off-white lyophilized powder and a single-dose prefilled syringe containing a clear, colorless solution (diluent) with a luer-lock adapter and soft inner tip cap
- Not made with natural rubber latex

Dosage Strength (per vial)	Color Cap Indicator	Carton NDC Number
9.5 mg/vial	Blue	63020-715-10
19 mg/vial†	Lime	63020-725-20
28 mg/vial	Burgundy	63020-735-30
41 mg/vial	Yellow	63020-745-40
54 mg/vial	White	63020-765-60

†The recommended starting dose of MIMRYLO is 19 mg SC injection once a week.

Specialty pharmacies will ship a **Welcome Kit** to each new MIMRYLO patient to help them get organized and reinforce injection training. It includes:

- Welcome Note
- Patient Brochure
- MIMRYLO Patient Support Flashcard
- Dosing and Administration Guide
- Prescribing Information
- Step-by-Step Injection Guide
- Demo Kit
- Injection Placemat
- Instructions for Use

Welcome Kit information

Please ensure your systems are updated with the above NDCs and product details

Storage and handling

- Store at room temperature between 68°F and 77°F (20°C to 25°C)
- Do not freeze
- Store in the original carton to protect from light
- Do not use the vial or the diluent prefilled syringe after the expiration date on the carton
- After reconstitution, administer MIMRYLO within 4 hours. Discard reconstituted solution if not used within 4 hours

Recommended dosing

- For subcutaneous use only
- Recommended starting dose: 19 mg once a week
- Dose of MIMRYLO may be adjusted based on efficacy and safety
- Maximum daily dose is 82 mg and maximum weekly dose is 108 mg
- Monitor CBC every 2 to 4 weeks or as clinically indicated during dose modifications

Takeda Oncology provides comprehensive patient support programs, including one-on-one nurse-led self-injection trainings where patients who have been prescribed MIMRYLO can receive expert guidance and support from one of our Nurse Navigators

Takeda Oncology Here2Assist®

Please see Important Safety Information on page 3 and accompanying full Prescribing Information.

Mimrylo™ rusfertide for injection

INDICATION

MIMRYLO is indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **New or Worsening Thrombocytosis:** MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.
- **Injection-Site Reactions:** Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.
- **Embryo-Fetal Toxicity:** Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.

ADVERSE REACTIONS

The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

USE IN SPECIFIC POPULATIONS

- **Lactation:** Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.
- **Females and Males of Reproductive Potential**
  - **Pregnancy Testing:** Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.
  - **Contraception:** Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-844-662-8532 or the FDA at 1-800-FDA-1088 or **www.fda.gov/medwatch**.

Please see accompanying MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

CBC, complete blood count; CT, Central Time; ET, Eastern Time; NCPDP, National Council for Prescription Drug Programs; NDC, National Drug Code; NPI, National Provider Identifier; SC, subcutaneous.

Reference: MIMRYLO. Prescribing Information. Takeda Pharmaceuticals America, Inc; 2026.

Takeda Oncology Here2Assist®

Takeda | ONCOLOGY

Mimrylo™ rusfertide for injection

TAKEDA and Takeda are registered trademarks of Takeda Pharmaceutical Company Limited.
MIMRYLO and are trademarks of Takeda Pharmaceuticals U.S.A., Inc.
HERE2ASSIST and are registered trademarks of Millennium Pharmaceuticals, Inc.
© 2026 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved. 09/26 US-RUS-0201